Premium
Effects of sarpogrelate hydrochloride in a patient with chronic graft‐versus‐host disease: a case report
Author(s) -
Hayashi Tomoe,
Morishita Eriko,
Ontachi Yasuo,
Yamazaki Masahide,
Asakura Hidesaku,
Yoshida Takashi,
Nakao Shinji
Publication year - 2006
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.20511
Subject(s) - medicine , graft versus host disease , complication , connective tissue disease , gastroenterology , lesion , antagonist , surgery , autoimmune disease , disease , dermatology , pathology , receptor
Chronic graft‐versus‐host disease (cGVHD) is a frequent complication of allogenic bone marrow transplantation. Even with aggressive treatment, cGVHD is associated with a significant degree of morbidity and mortality. cGVHD resembles autoimmune disorder, particularly systemic sclerosis (SSc). Sarpogrelate hydrochloride (SH) is an antagonist of the 5‐hydroxytryptamine 2A (5HT 2A ) receptor and has been reported to be effective in the treatment of systemic sclerosis (SSc) patients with Raynaud phenomenon. We used SH to treat a cGVHD patient, and we measured plasma PDGF and total TGF‐β levels. After SH treatment, his plasma PDGF and total TGF‐β levels decreased, and he noticed improvement in his skin pigmentation. In the present case, SH may have improved the skin lesion by inhibiting the synthesis of PDGF and TGF‐β. Am. J. Hematol. 81:121–123, 2006. © 2006 Wiley‐Liss, Inc.